STOCK TITAN

Takeda Pharmaceutical Company (TAK) Stock News, May-Jul 2021

TAK NYSE

Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.

Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.

Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced a collaboration with Frazier Healthcare Partners to launch HilleVax, Inc. for developing and commercializing its norovirus vaccine candidate, HIL-214. Takeda has licensed exclusive rights for HIL-214's development outside Japan while retaining rights in Japan. The vaccine candidate has shown efficacy in preventing moderate-to-severe norovirus cases and has been studied in nine clinical trials. This partnership allows Takeda to focus on other vaccines, including those for dengue and COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the FDA granted Breakthrough Therapy Designation to TAK-994, an oral orexin agonist in Phase 2 trials for treating excessive daytime sleepiness (EDS) in narcolepsy type 1 patients. This designation aims to expedite development for serious conditions and indicates promising preliminary clinical data suggesting improved wakefulness metrics. TAK-994 represents a significant step in addressing orexin deficiency in NT1 and is part of Takeda's innovative neuroscience research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
-
Rhea-AI Summary

Takeda has announced the results of a phase 3 trial for recombinant von Willebrand factor (rVWF) prophylaxis, presented at the ISTH Virtual Congress 2021. The study involved 23 patients with severe von Willebrand disease (VWD) over 12 months. Results indicated a 91.5% reduction in spontaneous, treated annualized bleeding rates (sABRs) compared to historical data from prior on-demand treatments. No new safety risks were identified, bolstering Takeda's commitment to improving patient outcomes in rare bleeding disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) has filed its Corporate Governance Report with the Tokyo Stock Exchange, as required for TSE listed companies. This report is based on the Corporate Governance Code effective since June 1, 2018, with a revised version due by December 2021. The report can be accessed on Takeda’s website. An English version has also been submitted to the U.S. Securities and Exchange Commission. For more information about Takeda's corporate governance policies and ESG initiatives, refer to their 2021 Annual Integrated Report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary

Takeda announced positive results from final analyses of the Phase 3 HELP Study™ Open-label Extension, demonstrating the long-term efficacy and safety of TAKHZYRO® (lanadelumab) for hereditary angioedema (HAE). The study involved 212 patients, revealing an 87.4% average reduction in attack rates, with up to 92.4% reduction during the steady state. The treatment maintained attack-free status for 58.6% of patients after six months. TAKHZYRO was well-tolerated across various demographics, with 54.7% experiencing treatment-related adverse effects. Results presented at the EAACI Congress reflect an important milestone for HAE management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.30%
Tags
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has filed its Annual Report on Form 20-F for the fiscal year ending March 31, 2021, with the SEC on June 29, 2021. The report is available on Takeda's website. Additionally, Takeda has published its 2021 Annual Integrated Report, accessible online. The company emphasizes its commitment to research and development in various therapeutic areas, including Oncology and Neuroscience, while offering free hard copies of the Annual Report to shareholders upon request.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary

Takeda has launched the "In Their Shoes" platform in the Middle East, an immersive simulation program aimed at increasing awareness of Inflammatory Bowel Disease (IBD) among healthcare providers. This innovative program allows participants to experience patient challenges through a mobile app and role-playing scenarios. An evaluation by the University of Westminster revealed significant improvements in empathy and understanding towards IBD patients. Since its inception, over 1,900 participants from more than 30 countries have engaged with the program, enhancing support for those affected by IBD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
-
Rhea-AI Summary

Takeda Pharmaceutical Company has reported positive results from the Phase 3 TAK-620-303 (SOLSTICE) trial for the investigational drug TAK-620 (maribavir), aimed at treating cytomegalovirus (CMV) infections in solid organ transplant (SOT) recipients. Achieving a 55.6% clearance rate at Study Week 8 for those treated with maribavir, compared to 26.1% for conventional therapies. Notably, lung transplant recipients showed a 47.5% success rate with maribavir. The trial met its primary endpoint with significantly fewer treatment-related toxicities. Maribavir is designed to offer a safer, more effective alternative for CMV infection treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
Rhea-AI Summary

Takeda announced promising results for its dengue vaccine candidate, TAK-003, showing sustained protection against dengue illness and hospitalization over three years. In the ongoing Phase 3 TIDES trial, involving over 20,000 children and adolescents, TAK-003 demonstrated an overall vaccine efficacy (VE) of 62.0% against confirmed dengue and an impressive 83.6% VE against hospitalized cases. No significant safety risks were identified, reinforcing TAK-003's potential impact in dengue-endemic regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.80%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical (TAK) last closed at $21.77.

What is the market cap of Takeda Pharmaceutical (TAK)?

The market cap of Takeda Pharmaceutical (TAK) is approximately $69.6B.